Launch week offerEnds in00h00m00s

annual Promonthly Pro

Renzhi Han

Has grant

Professor

Indiana University School of Medicine

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in United States Professors in Cell Biology Cell Biology professors in United States

About

Renzhi Han is a Professor at Indiana University School of Medicine in the United States. His research focuses on therapeutic gene-editing technologies, including the development of an oversized AAV8 vector for CPS1 delivery and base editing applications in models of Duchenne muscular dystrophy. His recent work also explores systemic delivery methods and mitochondrial therapeutics aimed at improving treatment outcomes in genetic disorders.

Recent Grants

Grant: Close

Mechanisms of Muscle Inflammation in Muscular Dystrophy

Open Date: 2013-07-05

Close Date: 2018-05-31

Grant: Close

Molecular and cellular functions of Ano5 in heart

Open Date: 2013-07-01

Close Date: 2018-03-31

Articles (22)

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (2)

Wenjun Zhang

Associate Research Professor

Indiana University School of Medicine

UNITED STATES

View details

PEIPEI WANG

Ohio State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Renzhi Han

Research Interests

Make your next move.

Explore related searches

About

Recent Grants

Articles (22)

Factor VIII originates primarily from anatomically distinct subsets of liver sinusoidal endothelial cells.

In vivo base editing of Asgr1 reduces blood lipids in mice

Dystrophin rescue in the brain for DMD

An oversized AAV8 vector to deliver CPS1

Recent advances in therapeutic gene-editing technologies

Rapidly evolving genome and epigenome editing technologies

Systemic delivery of full-length dystrophin in Duchenne muscular dystrophy mice

Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response

Targeting miR-25 to alleviate DMD-related muscle dysfunction.

Base editing in humanized dystrophic mice

Hit-and-run epigenome editing durably lowers cholesterol in mice

First in vivo base-editing trial shows promise

Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice

Defective BVES-mediated feedback control of cAMP in muscular dystrophy

Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping

Systemic AAV9.BVES delivery ameliorates muscular dystrophy in a mouse model of LGMDR25

MYBPC3 deficiency in cardiac fibroblasts drives their activation and contributes to fibrosis

BVES is a novel interactor of ANO5 and regulates myoblast differentiation

Pathological alterations in the gastrointestinal tract of a porcine model of DMD

Efficient precise in vivo base editing in adult dystrophic mice

Genome-wide CRISPR screen identifies LGALS2 as an oxidative stress-responsive gene with an inhibitory function on colon tumor growth

An open-source video tracking system for mouse locomotor activity analysis

Collaborators (2)

Wenjun Zhang

PEIPEI WANG

Make your next move.